dc.contributor.author | Kim, Y | |
dc.contributor.author | Bae, S | |
dc.contributor.author | Jeong, MH | |
dc.contributor.author | Ahn, Y | |
dc.contributor.author | Kim, CJ | |
dc.contributor.author | Cho, MC | |
dc.contributor.author | Baumbach, A | |
dc.contributor.author | Gogas, BD | |
dc.contributor.author | King, SB | |
dc.contributor.author | Other Korea Acute Myocardial Infarction Registry Investigators | |
dc.date.accessioned | 2020-11-11T15:24:42Z | |
dc.date.available | 2020-06-19 | |
dc.date.available | 2020-11-11T15:24:42Z | |
dc.date.issued | 2020-07-09 | |
dc.identifier.citation | : Kim Y, Bae S, Jeong MH, Ahn Y, Kim CJ, Cho MC, et al. (2020) One-year efficacy and safety of everolimus-eluting bioresorbable scaffolds in the setting of acute myocardial infarction. PLoS ONE 15(7): e0235673. https://doi.org/10.1371/journal. pone.0235673 | en_US |
dc.identifier.uri | https://qmro.qmul.ac.uk/xmlui/handle/123456789/68200 | |
dc.description.abstract | BACKGROUND AND OBJECTIVES: This study sought to compare clinical outcomes between bioresorbable scaffolds (BRS) and durable polymer everolimus-eluting metallic stents (DP-EES) in patients with acute myocardial infarction (AMI) undergoing successful percutaneous coronary intervention (PCI). METHODS: From March 2016 to October 2017, 952 patients with AMI without cardiogenic shock undergoing successful PCI with BRS (n = 136) or DP-EES (n = 816) were enrolled from a multicenter, observational Korea Acute Myocardial Infarction Registry. RESULTS: In the crude population, there was no significant difference in the 1-year rate of device-oriented composite endpoint (DOCE) and device thrombosis between the BRS and DP-EES groups (2.2% vs. 4.8%, hazard ratio [HR] 0.43, 95% confidence interval [CI] 0.13-1.41, p = 0.163; 0.7% vs. 0.5%, HR 1.49, 95% CI 0.16-13.4, p = 0.719, respectively). BRS implantation was opted in younger patients (53.7 vs. 62.6 years, p < 0.001) with low-risk profiles, and intravascular image-guided PCI was more preferred in the BRS group (60.3% vs. 27.2%, p < 0.001). CONCLUSIONS: At 1-year follow-up, no differences in the rate of DOCE and device thrombosis were observed between patients with AMI treated with BRS and those treated with DP-EES. Our data suggest that imaging-guided BRS implantation in young patients with low risk profiles could be a reasonable strategy in the setting of AMI. | en_US |
dc.format.extent | e0235673 - ? | |
dc.language | eng | |
dc.language.iso | en_US | en_US |
dc.publisher | Public Library of Science | en_US |
dc.relation.ispartof | PLoS One | |
dc.rights | Creative Commons Attribution License | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.subject | Absorbable Implants | en_US |
dc.subject | Acute Disease | en_US |
dc.subject | Adult | en_US |
dc.subject | Aged | en_US |
dc.subject | Cardiovascular Agents | en_US |
dc.subject | Drug-Eluting Stents | en_US |
dc.subject | Endpoint Determination | en_US |
dc.subject | Everolimus | en_US |
dc.subject | Female | en_US |
dc.subject | Humans | en_US |
dc.subject | Male | en_US |
dc.subject | Middle Aged | en_US |
dc.subject | Myocardial Infarction | en_US |
dc.subject | Percutaneous Coronary Intervention | en_US |
dc.subject | Proportional Hazards Models | en_US |
dc.subject | Republic of Korea | en_US |
dc.subject | Thrombosis | en_US |
dc.subject | Tissue Scaffolds | en_US |
dc.subject | Treatment Outcome | en_US |
dc.title | One-year efficacy and safety of everolimus-eluting bioresorbable scaffolds in the setting of acute myocardial infarction. | en_US |
dc.type | Article | en_US |
dc.rights.holder | © 2020 Kim et al. | |
dc.identifier.doi | 10.1371/journal.pone.0235673 | |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/32645029 | en_US |
pubs.issue | 7 | en_US |
pubs.notes | Not known | en_US |
pubs.publication-status | Published online | en_US |
pubs.volume | 15 | en_US |
dcterms.dateAccepted | 2020-06-19 | |
rioxxterms.funder | Default funder | en_US |
rioxxterms.identifier.project | Default project | en_US |